Public deck

AIDX: OneTest has revenue growth, but the new Nasdaq float is dilution math

20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.